253 related articles for article (PubMed ID: 31334926)
1. Non-Submental Applications of Injectable Deoxycholic Acid: A Systematic Review.
Sung CT; Lee A; Choi F; Juhasz M; Mesinkovska NA
J Drugs Dermatol; 2019 Jul; 18(7):675-680. PubMed ID: 31334926
[TBL] [Abstract][Full Text] [Related]
2. The Use of Deoxycholic Acid for the Clinical Reduction of Excess Submental Fat in Indian Patients.
Shome D; Khare S; Kapoor R
J Drugs Dermatol; 2019 Mar; 18(3):266-272. PubMed ID: 30909331
[TBL] [Abstract][Full Text] [Related]
3. ATX-101 (deoxycholic acid injection) for reduction of submental fat.
Ascher B; Fellmann J; Monheit G
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1131-43. PubMed ID: 27457304
[TBL] [Abstract][Full Text] [Related]
4. Alternative Cosmetic and Medical Applications of Injectable Deoxycholic Acid: A Systematic Review.
Liu C; Li MK; Alster TS
Dermatol Surg; 2021 Nov; 47(11):1466-1472. PubMed ID: 34537786
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events of Injectable Deoxycholic Acid.
Pham CT; Lee A; Sung CT; Choi F; Juhasz M; Mesinkovska NA
Dermatol Surg; 2020 Jul; 46(7):942-949. PubMed ID: 31977503
[TBL] [Abstract][Full Text] [Related]
6. Future Applications of Deoxycholic Acid in Body Contouring.
Sykes JM; Allak A; Klink B
J Drugs Dermatol; 2017 Jan; 16(1):43-46. PubMed ID: 28095531
[TBL] [Abstract][Full Text] [Related]
7. Deoxycholic Acid (ATX-101) for Reduction of Submental Fat.
Dunican KC; Patel DK
Ann Pharmacother; 2016 Oct; 50(10):855-61. PubMed ID: 27340142
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Zarbafian M; Karavan M; Greene R; Fabi SG
J Cosmet Dermatol; 2020 Jun; 19(6):1328-1332. PubMed ID: 31553141
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study.
Ascher B; Hoffmann K; Walker P; Lippert S; Wollina U; Havlickova B
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1707-15. PubMed ID: 24605812
[TBL] [Abstract][Full Text] [Related]
10. ATX-101 for reduction of submental fat.
Wollina U; Goldman A
Expert Opin Pharmacother; 2015 Apr; 16(5):755-62. PubMed ID: 25724831
[TBL] [Abstract][Full Text] [Related]
11. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat.
Dover JS; Kenkel JM; Carruthers A; Lizzul PF; Gross TM; Subramanian M; Beddingfield FC
Dermatol Surg; 2016 Nov; 42 Suppl 1():S288-S299. PubMed ID: 27787269
[TBL] [Abstract][Full Text] [Related]
12. Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications.
Farina GA; Cherubini K; de Figueiredo MAZ; Salum FG
J Cosmet Dermatol; 2020 Oct; 19(10):2497-2504. PubMed ID: 32654409
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.
Dayan SH; Schlessinger J; Beer K; Donofrio LM; Jones DH; Humphrey S; Carruthers J; Lizzul PF; Gross TM; Beddingfield FC; Somogyi C
Aesthet Surg J; 2018 Aug; 38(9):998-1010. PubMed ID: 29401213
[TBL] [Abstract][Full Text] [Related]
14. Sodium Deoxycholate for Submental Contouring.
Humphrey S; Beleznay K; Beleznay JD
Skin Therapy Lett; 2016 Sep; 21(5):1-4. PubMed ID: 27603325
[TBL] [Abstract][Full Text] [Related]
15. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction.
Jones DH; Carruthers J; Joseph JH; Callender VD; Walker P; Lee DR; Subramanian M; Lizzul PF; Gross TM; Beddingfield FC
Dermatol Surg; 2016 Jan; 42(1):38-49. PubMed ID: 26673433
[TBL] [Abstract][Full Text] [Related]
16. Deoxycholic Acid (ATX-101) for Fat Reduction.
Gupta J; Kassir M; Kroumpouzos G; Katsambas A; Galadari H; Lotti T; Wollina U; Grabbe S; Goldust M
J Drugs Dermatol; 2021 Nov; 20(11):1169-1173. PubMed ID: 34784130
[TBL] [Abstract][Full Text] [Related]
17. ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results From a 12-Month Open-Label Study.
Beer K; Weinkle SH; Cox SE; Rubin MG; Shamban A; Somogyif C
J Drugs Dermatol; 2019 Sep; 18(9):870-877. PubMed ID: 31524342
[TBL] [Abstract][Full Text] [Related]
18. A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.
Walker P; Fellmann J; Lizzul PF
J Drugs Dermatol; 2015 Mar; 14(3):279-87. PubMed ID: 25738850
[TBL] [Abstract][Full Text] [Related]
19. ATX-101 (Deoxycholic Acid Injection) Treatment in Men: Insights From Our Clinical Experience.
Shridharani SM; Behr KL
Dermatol Surg; 2017 Nov; 43 Suppl 2():S225-S230. PubMed ID: 28902021
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience With 100 Consecutive Patients Undergoing Neck Contouring With ATX-101 (Deoxycholic Acid): An Updated Report With A 2-Year Analysis.
Shridharani SM
Dermatol Surg; 2019 Oct; 45(10):1285-1293. PubMed ID: 30789506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
